Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

183,158 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Methylene amine substituted arylindenopyrimidines as potent adenosine A(2A)/A(1) antagonists.
Shook BC, Rassnick S, Hall D, Rupert KC, Heintzelman GR, Hansen K, Chakravarty D, Bullington JL, Scannevin RH, Magliaro B, Westover L, Carroll K, Lampron L, Russell R, Branum S, Wells K, Damon S, Youells S, Li X, Osbourne M, Demarest K, Tang Y, Rhodes K, Jackson PF. Shook BC, et al. Among authors: li x. Bioorg Med Chem Lett. 2010 May 1;20(9):2864-7. doi: 10.1016/j.bmcl.2010.03.042. Epub 2010 Mar 11. Bioorg Med Chem Lett. 2010. PMID: 20347304
Inhibitors of unactivated p38 MAP kinase.
Bullington J, Argentieri D, Averill K, Carter D, Cavender D, Fahmy B, Fan X, Hall D, Heintzelman G, Jackson P, Leung WP, Li X, Ling P, Olini G, Razler T, Reuman M, Rupert K, Russell R, Siekierka J, Wadsworth S, Wolff R, Xiang B, Zhang YM. Bullington J, et al. Among authors: li x. Bioorg Med Chem Lett. 2006 Dec 1;16(23):6102-6. doi: 10.1016/j.bmcl.2006.08.101. Epub 2006 Sep 12. Bioorg Med Chem Lett. 2006. PMID: 16971122
Synthesis and evaluation of pyrazolo[3,4-b]pyridine CDK1 inhibitors as anti-tumor agents.
Lin R, Connolly PJ, Lu Y, Chiu G, Li S, Yu Y, Huang S, Li X, Emanuel SL, Middleton SA, Gruninger RH, Adams M, Fuentes-Pesquera AR, Greenberger LM. Lin R, et al. Among authors: li s, li x. Bioorg Med Chem Lett. 2007 Aug 1;17(15):4297-302. doi: 10.1016/j.bmcl.2007.05.029. Epub 2007 May 16. Bioorg Med Chem Lett. 2007. PMID: 17532631
Optimization of arylindenopyrimidines as potent adenosine A(2A)/A(1) antagonists.
Shook BC, Rassnick S, Chakravarty D, Wallace N, Ault M, Crooke J, Barbay JK, Wang A, Leonard K, Powell MT, Alford V, Hall D, Rupert KC, Heintzelman GR, Hansen K, Bullington JL, Scannevin RH, Carroll K, Lampron L, Westover L, Russell R, Branum S, Wells K, Damon S, Youells S, Beauchamp D, Li X, Rhodes K, Jackson PF. Shook BC, et al. Among authors: li x. Bioorg Med Chem Lett. 2010 May 1;20(9):2868-71. doi: 10.1016/j.bmcl.2010.03.024. Epub 2010 Mar 7. Bioorg Med Chem Lett. 2010. PMID: 20338760
In vivo characterization of a dual adenosine A2A/A1 receptor antagonist in animal models of Parkinson's disease.
Shook BC, Rassnick S, Osborne MC, Davis S, Westover L, Boulet J, Hall D, Rupert KC, Heintzelman GR, Hansen K, Chakravarty D, Bullington JL, Russell R, Branum S, Wells KM, Damon S, Youells S, Li X, Beauchamp DA, Palmer D, Reyes M, Demarest K, Tang Y, Rhodes K, Jackson PF. Shook BC, et al. Among authors: li x. J Med Chem. 2010 Nov 25;53(22):8104-15. doi: 10.1021/jm100971t. Epub 2010 Oct 25. J Med Chem. 2010. PMID: 20973483
Design and characterization of optimized adenosine A₂A/A₁ receptor antagonists for the treatment of Parkinson's disease.
Shook BC, Rassnick S, Wallace N, Crooke J, Ault M, Chakravarty D, Barbay JK, Wang A, Powell MT, Leonard K, Alford V, Scannevin RH, Carroll K, Lampron L, Westover L, Lim HK, Russell R, Branum S, Wells KM, Damon S, Youells S, Li X, Beauchamp DA, Rhodes K, Jackson PF. Shook BC, et al. Among authors: li x. J Med Chem. 2012 Feb 9;55(3):1402-17. doi: 10.1021/jm201640m. Epub 2012 Jan 26. J Med Chem. 2012. PMID: 22239465
183,158 results
You have reached the last available page of results. Please see the User Guide for more information.